Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy starts working from the very first dose, but noticeable weight loss usually takes longer than most people expect. In the STEP 1 clinical trial, significant average weight reduction built up over months, not days, with many participants seeing meaningful change from around week four onwards. Semaglutide is a prescription-only medicine; a prescriber assesses whether it is clinically suitable for you before any treatment begins. If you have started a course and feel like nothing is happening yet, you are not unusual. A lot of people reach week two or three and quietly wonder whether their pen is even working. It almost certainly is — it is just that the earliest effects are mostly internal.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people starting Wegovy expect to feel different almost immediately. When the first week passes without a dramatic drop on the scales, worry sets in. The reality is that the 0.25 mg starting dose is a tolerability dose. Its job is to let your digestive system and appetite-regulating pathways adjust to semaglutide, not to deliver the full therapeutic effect. Think of it less as the treatment beginning and more as your body being introduced to it.
What you may notice at this stage is subtle. A slightly smaller appetite at mealtimes. Feeling full a little sooner than usual. Some people notice nausea, particularly after eating too quickly or eating fatty foods, which is the medicine's effect on gastric emptying becoming tangible. These are signs that semaglutide is doing exactly what it should, even when the mirror says otherwise.
The full Wegovy overview covers how this GLP-1 receptor agonist works in more detail, including its effect on hunger hormones and the rate at which food leaves the stomach. Understanding the mechanism makes the slow start feel considerably less frustrating.
The dose increases roughly every four weeks under your prescriber's guidance. As semaglutide levels in your body climb, appetite suppression deepens and the calorie deficit that drives weight loss becomes more consistent. If you are curious about how soon Wegovy works for most people, there is real individual variation in when noticeable weight change arrives, though the four-to-twelve-week window is where most people see it.
By the time someone reaches the 1.0 mg or 1.7 mg dose stage, cravings for particular foods often quieten. Portion sizes tend to shrink without it feeling like restriction. This is the phase where the medicine's effect on the brain's reward pathways, not just the stomach, becomes most apparent. Food simply stops occupying so much mental space.
It is also the phase where side effects are most commonly reported. Nausea, loose stools and reflux are the most frequent, and they tend to peak after a dose increase before settling. The semaglutide clinical profile outlines these patterns clearly, including which symptoms typically resolve on their own and which warrant a call to your prescriber.
For context on how Wegovy sits within the broader range of weight management options, the weight loss treatments overview is a useful reference.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults taking semaglutide 2.4 mg for 68 weeks alongside lifestyle changes. Average weight loss was approximately 15% of starting body weight. That figure did not arrive quickly. It was the cumulative result of sustained appetite reduction across many months at the maintenance dose.
The lesson here is that Wegovy's timeline rewards patience in a way that quick-fix approaches never do. Understanding how soon Wegovy starts working helps set realistic expectations, because the earlier months lay the physiological groundwork while the later months deliver the compound effect. Stopping early (before reaching the maintenance dose or before giving the maintenance dose enough time) means missing most of the benefit.
The NHS medicines page for semaglutide provides patient-level information on what to expect during treatment, including guidance on side effects and when to contact a healthcare professional. It is worth reading alongside the Patient Information Leaflet that comes with your pens.
If you are considering whether Wegovy is the right option for you, our guide to what Wegovy is licensed for explains the eligibility criteria in plain language. And if you have questions about how the private prescription route works, our frequently asked questions cover the process from consultation to delivery.
Starting weight, metabolic health, sleep quality, how closely a calorie-reduced diet is followed, and how much physical activity is built into daily life all influence how quickly Wegovy produces visible results. None of this means the medicine is failing if progress is slower than average, it means the full picture is more nuanced than a single number on a leaflet.
Some people also respond differently at different dose stages. A person who sees little change at 0.5 mg may find 1.7 mg delivers a marked shift. This is one reason prescribers titrate carefully rather than starting everyone at the highest dose immediately.
If you are weighing up costs as part of your decision, our private Wegovy prescription page sets out clearly what is included in a private service and what to look for in a legitimate, GPhC-registered provider. At nume (at nume) every consultation is reviewed personally by a GPhC-registered Independent Prescriber, and aftercare is available seven days a week so questions like these never go unanswered.
When you are ready to speak with someone clinical about your own situation, speak to our prescribers through a free consultation, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.